Format

Send to

Choose Destination
Immunotherapy. 2015;7(1):1-2. doi: 10.2217/imt.14.110.

Could PD-L1 prove to be an effective therapeutic target for bladder cancer?

Author information

1
Yale Comprehensive Cancer Center, Yale School of Medicine, 333 Cedar Street, Fitkin 3, New Haven, CT 06520-8028, USA.

KEYWORDS:

immune checkpoint inhibition; urothelial bladder cancer

PMID:
25572474
DOI:
10.2217/imt.14.110
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center